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Abstract
Successful kidney transplantation offers patients with end-stage renal disease the greatest likelihood of survival. However, 
cardiovascular disease poses a major threat to both graft and patient survival in this cohort. Transplant recipients are unique 
in their accumulation of a wide range of traditional and non-traditional cardiovascular risk factors. Hypertension, diabetes, 
dyslipidaemia and obesity are highly prevalent in patients with end-stage renal disease. These risk factors persist following 
transplantation and are often exacerbated by the drugs used for immunosuppression in organ transplantation. Additional 
transplant-specific factors such as poor graft function and proteinuria are also associated with increased cardiovascular risk. 
However, these transplant-related factors remain unaccounted for in current cardiovascular risk prediction models, mak-
ing it challenging to identify transplant recipients with highest risk. With few interventional trials in this area specific to 
transplant recipients, strategies to reduce cardiovascular risk are largely extrapolated from other populations. Aggressive 
management of traditional cardiovascular risk factors remains the cornerstone of prevention, though there is also a potential 
role for selecting immunosuppression regimens to minimise additional cardiovascular injury.
Keywords Kidney transplant · Cardiovascular disease · Risk factors · Immunosuppression · Biomarkers
Introduction
End-stage renal disease (ESRD) is an irreversible condition 
which results in a significant reduction in individual life 
expectancy and has major treatment costs. Options for renal 
replacement therapy (RRT) are limited to different modali-
ties of dialysis or kidney transplantation. Transplantation is 
considered the optimal form of RRT due to the numerous 
benefits conferred by a functioning allograft compared to 
dialysis. Chief among these are increased patient survival 
and improved quality of life [1, 2]. However, transplanta-
tion is not a panacea for the many metabolic derangements 
brought about by ESRD. Despite significant surgical and 
immunopharmacological advancements, renal transplant 
recipients (RTR) do not share the life expectancy of their 
age-matched peers. While a healthy 20-year-old individual 
in Europe can expect to live a further 62 years, the same 
individual can expect to live 44 years following a successful 
renal transplant and only 22 years upon commencing chronic 
dialysis [3].
This discrepancy in life expectancy is at least partially 
attributable to the increased incidence of cardiovascular 
disease that occurs in patients with ESRD. The risk of car-
diovascular disease in patients undergoing regular haemo-
dialysis is estimated to be 10–20 times higher than that of 
the general population [4]. While a successful transplant 
can reduce this risk significantly, RTR still have an annual 
cardiovascular event rate of 3.5–5% [5]. Accordingly, cardio-
vascular disease remains one of the leading causes of death 
in RTR [6, 7]. As death with a functioning graft is the lead-
ing cause of graft loss [8], potential strategies to successfully 
reduce the burden of cardiovascular disease are essential for 
improving both graft and patient outcomes.
In this review, we provide insights into both traditional 
and non-traditional factors which interact to contribute to 
the increased risk of cardiovascular disease in RTR. The 
challenges posed by identifying those RTR at highest 
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cardiovascular risk are emphasised and some of the poten-
tial measures that may be employed to reduce this risk are 
described.
Epidemiology
In comparison to their age-matched peers, RTR display a 
three- to five-fold increased risk of cardiovascular disease 
[9]. Over 50% of cardiovascular-related deaths in RTR are 
sudden, and presumed to be secondary to cardiac arrhyth-
mia and cardiac arrest [7]. Thus, non-atherosclerotic cardiac 
disease appears to be of particular importance in this cohort. 
This likely represents the high burden of structural cardiac 
abnormalities, such as myocardial fibrosis and left ventricu-
lar hypertrophy (LVH), present in patients with ESRD com-
mencing RRT [10].
The clinical pattern of cardiovascular disease observed 
in RTR is otherwise broadly similar to that observed in 
non-transplanted individuals. The incidence of myocar-
dial infarction (MI) is high with rates of 5.6% and 11.1% at 
1 year and 3 years post-transplantation, respectively [11]. 
This is approximately six-fold higher than observed in the 
general population [11]. Congestive heart failure is also an 
important cause of cardiovascular mortality [7, 12].
Registry data from the USA have consistently identi-
fied cardiovascular disease as the leading cause of death in 
RTR [7]. However, recent data from the UK Renal Registry 
demonstrate that the annual mortality directly attributable 
to cardiovascular disease in RTR has fallen over the last 
decade [6]. Despite this, cardiovascular disease remains a 
significant clinical problem and is responsible for approxi-
mately 20–35% of mortality in RTR [6, 7].
Traditional cardiovascular risk factors
The first results of the Framingham Heart Study published 
in 1957 identified hypercholesterolaemia and hypertension 
as risk factors for the development of cardiovascular disease 
[13]. Subsequently smoking, obesity and diabetes mellitus 
were identified as being important. These “traditional” car-
diovascular risk factors are also strongly associated with the 
development of chronic kidney disease (CKD). Their preva-
lence is therefore markedly increased among RTR, who may 
have had a prolonged duration of accelerated cardiovascular 
risk prior to transplantation (Table 1) [14, 15].
Hypertension
Hypertension is already present in over 60% of patients prior 
to transplantation [14]. It usually persists post-transplant 
and is exacerbated by some immunosuppressive drugs e.g. 
calcineurin inhibitors [16]. Other potential contributory fac-
tors include graft dysfunction and transplant renal artery 
stenosis. The prevalence of hypertension in RTR is report-
edly greater than 70% [17].
Hypertension is associated with graft failure, cardiovas-
cular disease and mortality [18, 19]. Kasiske and colleagues 
found that each 10 mmHg increase in systolic blood pressure 
(SBP) is associated with an 18% increase in the risk of death 
in RTR [18].
A recent study by Mallamaci and co-workers highlighted 
the prognostic significance of ambulatory blood pressure 
monitoring (ABPM) in RTR [20]. They demonstrated that 
the prevalence of nocturnal hypertension is greater than dou-
ble that of daytime hypertension in RTR, and that nocturnal 
blood pressure is a stronger predictor of graft failure than 
daytime values [20]. ABPM is particularly useful in identi-
fying masked hypertension, which is a common problem in 
this population [21].
The optimal blood pressure target in RTR remains unclear 
due to a lack of prospective trials. Recommendations are 
often based on observational and retrospective data. The 
Collaborative Transplant Study showed that risk of cardio-
vascular mortality and graft failure is reduced when SBP is 
< 140 mmHg at 3 years post-transplant [22]. Another study 
by the same group demonstrated that SBP < 120 mmHg 
is associated with improved graft survival compared to 
SBP < 130 mmHg [23]. Current KDIGO guidelines recom-
mend a target blood pressure of < 130/80 mmHg for all RTR, 
whereas guidelines in the UK set a target of < 140/90 mmHg 
in the absence of proteinuria [24, 25].
The existing evidence-base is insufficient to recommend 
the use of one antihypertensive agent over another in RTR. 
Clearly there are circumstances in which one particular class 
of drug may be more desirable. Calcium channel blockers 
can counteract the vasoconstrictive effects of calcineurin 
inhibitors [16]. ACE-inhibitors (ACEi) and angiotensin-
receptor blockers (ARB) are useful in reducing proteinuria 
and can ameliorate post-transplant erythrocytosis, (which 
has been postulated to potentially be of relevance), though 
their use in the very early post-transplant period requires 
Table 1  Cardiovascular risk factors in renal transplant recipients</
tb>
a Exacerbated by steroid use
b Exacerbated by calcineurin inhibitor use
Traditional risk factors Non-traditional risk factors
Hypertensiona,b Renal impairment (reduced eGFR)
Diabetes  mellitusa,b Proteinuria
Cigarette smoking Left ventricular hypertrophy
Dyslipidaemiaa,b Anaemia
Obesitya Acute rejection episodes
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close monitoring [24–26]. Irrespective of the choice of anti-
hypertensive drug(s), the aim should be to achieve adequate 
blood pressure control to improve graft and patient survival.
Diabetes mellitus
Diabetes mellitus is highly prevalent in RTR. In Europe, 
26% of patients with ESRD have diabetic nephropathy reg-
istered as their primary renal disease [27]. A proportion of 
these patients proceed to transplantation. In addition, RTR 
without pre-existing diabetes are at risk of developing post-
transplantation diabetes mellitus (PTDM).
Kasiske and colleagues demonstrated that for RTR with 
pre-existing diabetes, the risk of cardiovascular disease 
and stroke is increased threefold compared to non-diabetic 
recipients [28]. The adjusted risk of peripheral vascular 
disease is also up to 28 times higher [28]. This heightened 
risk may reflect progression of subclinical cardiovascular 
disease which was present at the time of transplantation but 
not identified during work-up. In a study by Ramanathan and 
co-workers of patients with ESRD, 33% of asymptomatic 
individuals with type 1 diabetes and 48% of persons with 
type 2 diabetes had significant coronary artery stenosis at 
angiogram [29]. Despite this, there is currently insufficient 
evidence to support routine use of coronary angiogram in 
the work-up for transplantation of asymptomatic individuals 
with diabetes.
PTDM is also strongly associated with increased cardio-
vascular risk in RTR [30]. Established risk factors include 
deceased donor graft, older recipient age, recipient ethnic-
ity (Hispanic), recipient race (black) and the presence of 
hypertension, obesity or substantial post-transplant weight 
gain. Use of calcineurin inhibitors and steroids also con-
tribute to PTDM risk by blunting insulin secretion and 
increasing insulin resistance [31]. Screening for PTDM is 
recommended at each clinic visit using dipstick urinalysis 
and blood glucose measurement. Formal diagnosis should be 
based on WHO criteria using HbA1c, fasting blood glucose 
level or the oral glucose tolerance test when the recipient is 
clinically stable [25].
The management of diabetes in RTR can be challenging 
and often requires specialist input from a diabetologist [25]. 
In early post-transplant hyperglycaemia, insulin is often 
required to counteract the effects of high-dose steroids [32]. 
However, in the outpatient setting, lifestyle measures such as 
weight loss and use of oral hypoglycaemic agents are appro-
priate initial steps. There is currently a dearth of evidence on 
the efficacy or safety of newer oral agents, such as sodium 
and glucose co-transporter 2 (SGLT2) inhibitors and gluca-
gon-like peptide 1 (GLP-1) agonists in RTR. As a result, 
an international consensus meeting in 2013 was unable to 
support the introduction of a hierarchy of hypoglycaemic 
agents for PTDM management [32]. Their recommendation 
was to alter the immunosuppressive regimen and introduce 
hypoglycaemic agents in an approach individualised to the 
patient.
However, studies in this field are ongoing (see Table 2). 
If demonstrated to be safe, the potential cardiovascular and 
renal protection offered by SGLT2 inhibitors and GLP-1 
agonists make them an appealing choice for RTR [33].
Dyslipidaemia
Dyslipidaemia is a common problem following transplanta-
tion, with over 60% of RTR affected [34]. Transplantation 
is associated with elevations of total cholesterol, LDL-cho-
lesterol and triglycerides, largely due to immunosuppression 
regimens. Steroids, calcineurin inhibitors and mTOR inhibi-
tors all have deleterious effects on lipid concentrations [35].
There is a strong association between dyslipidaemia and 
cardiovascular disease in RTR. The risk of ischaemic heart 
disease is doubled with serum cholesterol > 200 mg/dL or 
triglycerides > 350 mg/dL [15]. Additionally, total choles-
terol concentration at 1-year post-transplant independently 
predicts mortality in RTR [28].
Screening for dyslipidaemia should be undertaken early 
following transplantation and then at least annually [24, 25]. 
Management can include reduction of immunosuppression 
doses or, where relevant, switching from ciclosporin to tac-
rolimus [36]. However, guidelines now recommend the use 
of HMG-CoA reductase inhibitors (statins) in RTR with 
hypercholesterolaemia [24, 25]. These are based on evidence 
from the ALERT trial [12], which showed fluvastatin suc-
cessfully lowered LDL-cholesterol by 32%. Although the 
trial was inadequately powered for its primary composite 
endpoint (major adverse cardiac events, MACE), fluvasta-
tin reduced the risk of cardiac death and non-fatal MI by 
35% [12]. Results from a post hoc analysis demonstrated 
that risk reduction was greatest when statin therapy was 
introduced within the first 2 years following transplantation 
[37]. Despite this evidence, uncertainty over target levels, 
poor tolerance of statin therapy in a substantial minority of 
patients, and the concern regarding polypharmacy, impacts 
on the widespread clinical prescription of statin therapy in 
this cohort.
Proprotein convertase subtilisin kexin type 9 (PCSK9) 
inhibitors have recently been used as adjunctive therapy to 
statins in patients who fail to achieve adequate cholesterol 
control [38]. These monoclonal antibodies lower cholesterol 
through their action on LDL-receptors in the liver, increas-
ing LDL uptake from the blood. In the FOURIER trial, 
evolocumab significantly lowered LDL-cholesterol concen-
tration and reduced the incidence of major cardiovascular 
events in patients already taking statins [39]. As a novel drug 
class, there is no experience of PCSK9 inhibitor use in RTR. 
However, it is important to note that the FOURIER trial 
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specifically excluded transplant recipients and those with 
advanced renal impairment. Therefore, further trials which 
include such patients are required before use of PCSK9 
inhibitors can be considered in RTR.
Cigarette smoking
Kasiske and Klinger published a study in 2000 reporting that 
25% of recipients smoked at the time of transplantation. The 
smoking prevalence in RTR mirrored the prevalence in the 
general population [40]. This study demonstrated that smok-
ing was an independent risk factor for graft loss, cardio-
vascular disease and death [40]. A recent post hoc analysis 
of the FAVORIT study demonstrated similar results, with 
continued smoking increasing the risk of all-cause mortal-
ity by 70% [41]. There are insufficient interventional trials 
investigating the efficacy of smoking cessation methods in 
RTR. However, methods used in the general population are 
likely to be safe and should be used [25].
Interestingly, the study by Kasiske and Klinger demon-
strated that smoking cessation more than 5 years prior to 
transplantation significantly reduced the risk of adverse out-
comes [40]. This suggests that smoking cessation strategies 
would be most effectively used in patients with CKD before 
they ever reach ESRD.
Weight gain and obesity
The global obesity epidemic is reflected in the renal trans-
plant population. Recent data showed that approximately 
35% of RTR in the USA are obese at the time of transplanta-
tion with a body mass index (BMI) ≥ 30 kg/m2. This figure is 
increasing annually as practice evolves to include higher risk 
recipients on the waiting list. No definitive safe upper limit 
for BMI at time of transplantation has been established [42]. 
Obese ESRD patients who are transplanted have improved 
survival rates compared to those who remain on dialysis 
[43]. In the current era, their risk of graft failure and death 
is comparable to those who undergo transplantation with a 
normal BMI [44].
Nevertheless, obesity is associated with cardiovascular 
disease. A study by Lentine and co-workers demonstrated 
that the risk of cardiac disease, particularly heart failure 
and atrial fibrillation, is increased by 25% for each 5 unit 
increase in recipient BMI [45]. Obesity is associated with 
hypertension, dyslipidaemia, impaired glucose tolerance 
and proteinuria in RTR, all of which increase cardiovascu-
lar risk [46]. A study by Johnson and colleagues revealed 
that weight gain is a common issue post-transplantation, 
with over half of RTR gaining more than 10% body weight 
[47]. Post-transplantation weight gain is also associated with 
adverse outcomes, even in the absence of obesity [47].
Weight loss may be aided with exercise and appropriate 
dietary advice, though there are no clinical trials to sup-
port this in RTR specifically. The use of pharmacological 
interventions to stimulate weight loss is not currently recom-
mended due to concerns these may interfere with the absorp-
tion of immunosuppressive drugs [25]. Steroid reduction or 
withdrawal may appear intuitive but the effect on obesity is 
limited [48].
Non‑traditional cardiovascular risk factors
With regards to cardiovascular risk, individuals with CKD 
and ESRD have unique characteristics given the combined 
effects of prolonged exposure to traditional risk factors com-
pounded by the accumulated burden of non-traditional risk 
factors related to CKD and ESRD (Table 3). A function-
ing allograft can mitigate the impact of some of these non-
traditional factors, but they typically persist to some degree 
following transplantation.
Renal impairment
Successful kidney transplantation and the restoration of 
renal function significantly reduces, but does not negate, the 
risk of cardiovascular mortality in recipients. Even an allo-
graft with excellent function does not restore to the recipient 
an entirely normal glomerular filtration rate (GFR). In this 
sense, transplant recipients should be considered a unique 
cohort of patients with enduring, albeit less advanced, CKD.
A study by Foster and colleagues demonstrated that esti-
mated GFR (eGFR), calculated from creatinine, cystatin C 
or β2-microglobulin, is an independent risk factor for cardio-
vascular events and mortality in RTR [49]. The highest level 
of incident cardiovascular disease and all-cause mortality 
is associated with the lowest eGFR. A post hoc analysis of 
the FAVORIT study suggested that this only becomes rel-
evant once the eGFR falls below 45 ml/min/1.73 m2, with no 
association with incident cardiovascular disease or all-cause 
mortality above this threshold. However, below this cut-off, 
each 5 ml/min/1.73 m2 increase in eGFR is associated with a 
15% reduction in cardiovascular disease and mortality [50].
Such studies have highlighted the importance of achiev-
ing, and subsequently maintaining, optimal graft function 
to favourably modify cardiovascular risk in RTR. Strate-
gies to improve graft longevity have long been considered, 
(increased use of living donor organs is one option), but 
there is yet to be consensus on the ideal immunosuppression 
regimen, which balances the risks of chronic immunolog-
ically-mediated damage and calcineurin inhibitor nephro-
toxicity [51].
 Journal of Nephrology
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Proteinuria
Proteinuria is a commonly identified issue in RTR. Its 
exact prevalence is difficult to ascertain due to the varying 
thresholds used in studies, but approximately 20% of RTR 
have proteinuria of greater than 1 g/day [52]. Analogous to 
its impact in the general population, proteinuria in RTR is 
associated with cardiovascular disease. A study by Fernan-
dez-Fresnedo and colleagues demonstrated that persistent 
proteinuria doubles the risk of cardiovascular disease and 
all-cause mortality in RTR [53].
Despite the widespread use of renin-angiotensin sys-
tem (RAS) blockade in patients with proteinuric CKD, the 
evidence-base in the transplant population is not definitive. 
A systematic review by Hiremath and colleagues, which 
included 21 trials and 1549 patients, demonstrated that 
RAS blockade effectively reduces proteinuria in RTR [54]. 
However, the median follow-up time of 27 months was insuf-
ficient to determine effects on graft and patient outcomes. A 
more recent systematic review by the same group failed to 
show a survival benefit from use of RAS blockade in RTR 
[55]. Additionally, a further retrospective study involving 
over 39,000 recipients demonstrated that use of RAS block-
ade did not reduce the risk of cardiovascular death compared 
to other forms of antihypertensive medication [56].
Nevertheless, UK and US guidelines continue to advo-
cate the use RAS blockage in RTR with proteinuria based 
on their ability to reduce urinary protein excretion [24, 25].
Table 3  Summary of studies 
relevant to the risk of 
cardiovascular disease in renal 
transplant recipients
Area of study Types of studies Reference number
Traditional cardiovascular risk factors
 Hypertension Observational–prospective
Observational–cross-sectional
Observational–retrospective
20
19
18, 22, 23
 Diabetes mellitus Registry data
Observational–retrospective
Consensus meeting
27
28, 29, 30
32
 Dyslipidaemia Observational–retrospective
Double-blind RCT 
Post-hoc analysis of RCT 
15, 28
12, 39
37
 Smoking Observational–retrospective
Post-hoc analysis of RCT 
40
41
 Obesity Systematic review
Observational–prospective
Observational–retrospective
Registry study
44
46
45, 47, 48
43
Non-traditional cardiovascular risk factors
 Renal impairment Nested case-control within RCT 
Post-hoc analysis of RCT 
49
50
 Proteinuria Systematic review
Meta-analysis
Observational–retrospective
54
55
53, 56
 Left ventricular hypertrophy Double-blind RCT 
Observational–prospective
Observational–retrospective
62
61
57
 Anaemia Systematic review
Observational–retrospective
54
57
 Acute rejection Observational–retrospective 15, 64
Immunosuppression-related cardiovascular risk
 Belatacept use Systematic review
Observational–retrospective
66
65
Cardiovascular risk prediction
 Renal transplant recipients Systematic review
Observational–prospective
Observational–retrospective
Validation on RCT data
71
69
64, 67, 68, 70
72, 73
Biomarkers of cardiovascular disease Post-hoc analysis of RCT 
Meta-analysis
Observational–prospective
80
75, 76, 77
78, 79
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Left ventricular hypertrophy
Although it may be classified as a form of cardiovascu-
lar disease in itself, LVH is an independent risk factor for 
congestive cardiac failure and mortality in RTR [57]. It is 
common in RTR and is closely linked to hypertension and 
anaemia [57].
Several methods exist for the diagnosis of LVH, includ-
ing electrocardiography (ECG), echocardiography (ECHO), 
and cardiac magnetic resonance imaging (CMRI) [58]. At 
present, use of CMRI for this purpose is not routine due to 
cost considerations and labour intensity. ECHO is subject 
to operator variability but is considered the gold-standard 
modality. It is portable, widely available and has been 
repeatedly used in both observational and interventional 
studies in RTR [58, 59]. When ECHO is used, LV mass 
must be corrected for body size either by indexing to body 
surface area (BSA) or height raised to the allometric power 
of 2.7  (height2.7). Both indexes have been used in studies 
involving RTR, and joint recommendations by the Ameri-
can Society of Echocardiography and the European Society 
of Cardiovascular Imaging do not favour use of one over 
the other. However,  height2.7 may have advantages in obese 
patients, which makes this index more applicable to RTR 
where obesity is common [60]. Although it is possible to 
diagnose LVH by ECG (and this diagnosis is associated with 
mortality in RTR), lack of sensitivity means ECG should be 
considered second-line [57, 58].
In one study, regression of LVH in RTR reduced the risk 
of cardiovascular events by 59% [61]. A randomised trial by 
Midtvedt and co-workers demonstrated that a functioning 
allograft and well-controlled blood pressure lead to LVH 
regression [62]. In this study, ACE inhibitors and calcium-
channel blockers were equally effective. Thus, achieving 
adequate blood pressure control should be viewed as more 
important than the agent used.
Increasingly, mammalian target of rapamycin (mTOR) 
inhibitors have been investigated as potential promoters of 
LVH regression. The mTOR signalling pathway is involved 
in modulating the cardiac response to haemodynamic 
stress. Several small randomised controlled trials in RTRs 
have shown reduction in LV mass with these agents used 
as immunosuppression [59]. Much larger randomised con-
trolled trials will be required to confirm these findings and 
investigate the impact on survival before mTOR inhibitors 
are routinely used for their cardiac remodelling properties.
Other non‑traditional risk factors
Several other risk factors for cardiovascular disease which 
are common in transplant recipients have been identified. 
Anaemia affects 20–45% of RTR [63]. It is attributed to a 
combination of factors including suboptimal graft function, 
RAS blockade, antiproliferative agents, mTOR inhibitors 
and co-trimoxazole [54, 63]. Akin to its impact in the CKD 
population, post-transplant anaemia is associated with the 
development of LVH and congestive heart failure [57]. Its 
impact on patient survival remains unclear [63]. Treatment 
in RTR should be analogous to management of anaemia in 
CKD patients [25]. However, caution must be exercised as 
over-correction has also been associated with increased mor-
tality risk in RTR [63].
A study by Kasiske and co-workers demonstrated that two 
or more episodes of acute rejection in the first year increases 
the risk of ischaemic heart disease by 62% [15]. The PORT 
study also found acute rejection associates with an increase 
in cardiovascular risk [64]. The underlying mechanism 
for this association remains unclear. It is possible that the 
immune activation which occurs in rejection is involved in 
the pathogenesis of cardiovascular disease. However, the 
effects of the additional immunosuppression used to treat 
rejection may also contribute to increased cardiovascular 
risk.
Immunosuppression and cardiovascular risk
Immunosuppression is essential post-transplantation to pre-
vent graft loss from acute rejection and chronic immunologi-
cal injury. Despite the positive impact immunosuppressant 
agents have on long-term graft outcomes, their negative 
effects on RTR are equally important. Steroids and cal-
cineurin inhibitors contribute significantly to the increased 
risk of cardiovascular disease faced by RTR. This occurs 
primarily through their amplification of traditional risk fac-
tors such as hypertension, diabetes and dyslipidaemia [16, 
31, 35]. While these risk factors can be addressed, this is 
often at the expense of using additional medications such 
as antihypertensives, insulin and statins. Therefore, steroid 
or calcineurin inhibitor avoidance has been suggested as an 
alternative strategy to reduce cardiovascular risk. Trial evi-
dence to define the optimal immunosuppression regimen for 
this purpose is lacking and the potential for increased risk 
of rejection must be borne in mind. Guidelines by the Renal 
Association in the UK advocate that a flexible approach to 
immunosuppression is required, with RTR being stratified 
by risk [25].
In recent years, attempts have been made to develop novel 
immunosuppressive agents to allow calcineurin inhibitor 
avoidance without risk of allograft rejection. Treatment 
with one such drug, belatacept, has been associated with 
an improvement in graft function, blood pressure and lipid 
profile, and a lower incidence of post-transplantation dia-
betes [65, 66]. However, these effects have not yet been 
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demonstrated to lead to an improvement in the long-term 
cardiovascular risk profile of belatacept treated-recipients.
Predicting cardiovascular risk
Various strategies to address the worldwide prevalence of 
cardiovascular disease have appropriately focused on pre-
vention rather than cure. Such an approach requires meth-
ods to identify at-risk individuals for targeted cardiovascular 
risk reduction. In the general population, various prediction 
models for cardiovascular risk have been developed for this 
purpose.
One potential pitfall when using cardiovascular risk 
scores is that they may under- or overestimate risk when 
used in an inappropriate patient group. Risk scores are 
validated for use only on the population from which they 
were derived. For example, the Framingham cohort were a 
homogenous group of individuals, predominantly white and 
middle-aged. Therefore, despite various updates and adjust-
ments, the Framingham risk score is limited in its ability 
to predict cardiovascular risk in the various ethnic groups 
worldwide. This was the primary motivation for the devel-
opment of QRISK and subsequently QRISK2 scores [67].
Several studies on cardiovascular risk prediction in RTR 
have applied the Framingham risk score. These studies dem-
onstrated that the risk score appropriately identifies recipi-
ents at low-risk. However, it greatly underestimates cardio-
vascular risk in recipients at moderate and high-risk [68–71]. 
Therefore, recipients in most need of effective preventative 
strategies may be overlooked.
This underestimation of risk in transplant recipients is 
partly because non-traditional risk factors play an important 
role but are unaccounted for in general population-based 
scores [69].
Transplant‑specific cardiovascular risk prediction
Several large studies have attempted to develop risk pre-
diction models specifically for use in RTR. In the PORT 
study, Israni and co-workers analysed both traditional and 
non-traditional risk factors for cardiovascular disease in over 
23,000 RTR [64]. They showed that important risk factors 
for prediction included age, sex, race, pre-existing diabetes, 
post-transplant diabetes, pre-existing cardiovascular disease, 
eGFR, acute rejection, delayed graft function and duration of 
ESRD. Further analysis revealed that traditional risk factors 
added little to the accuracy of the model. The non-traditional 
factors included in their risk prediction score were closely 
related to graft function.
In 2012, Soveri and colleagues developed the cardiovas-
cular risk calculator for renal transplant recipients (CRC RTR 
-MACE), which provides an estimate of risk over 7 years 
[72]. This calculator was established using seven variables 
including age, previous ischaemic heart disease, diabetes, 
LDL-cholesterol, serum creatinine, number of previous 
transplants and smoking status. The authors proceeded to 
validate its use in RTR using individuals in an international 
database and two clinical trials [73]. When compared to 
Framingham risk score, the CRC RTR -MACE more accu-
rately predicted the risk of cardiovascular events in RTR. 
The improvement in risk prediction with CRC RTR -MACE 
appears to be primarily related to the addition of GFR to 
traditional risk factors [68].
Biomarkers of cardiovascular disease
Risk prediction models based on traditional cardiovascular 
risk factors remain the cornerstone of effective prevention. 
However, these models have limitations and fail to iden-
tify every individual who will develop cardiovascular dis-
ease. Attempts have therefore been made to improve their 
accuracy through the addition of other risk markers, often 
termed “biomarkers.” In the general population, a vast array 
of biomarkers of cardiovascular disease has been identified, 
with the utility of up to 30 markers being investigated in one 
study [74]. A single biomarker is unlikely to outperform and 
therefore replace an existing risk prediction model. Rather, 
biomarkers are studied as potential adjuncts to be incorpo-
rated into established models.
Several widely-used cardiovascular biomarkers, meas-
ured in serum, have been extensively studied in patients 
with renal disease. The concentrations of Troponin T (TnT) 
and N-terminal B-type natriuretic peptide (NT-proBNP) are 
strongly correlated with eGFR and as a result, their inter-
pretation can be challenging. Despite this, both biomarkers 
appear to retain their predictive value in various groups of 
patients with renal disease. Elevations of TnT are associated 
with all-cause and cardiovascular mortality in patients with 
CKD [75]. In 2013, a meta-analysis including 27 studies 
found an association between elevated serum NT-proBNP 
concentration and cardiovascular mortality in ESRD patients 
[76].
C-reactive protein (CRP) may also be useful as a prognos-
tic biomarker in patients with ESRD. A systematic review of 
109 studies found that CRP concentration was strongly asso-
ciated with cardiovascular death in dialysis patients [77].
Research into the use of circulating cardiovascular bio-
markers specifically in RTR has been more limited. A study 
by Connolly and co-workers demonstrated that TnT con-
centration is a strong predictor of cardiovascular mortal-
ity in this population [78]. Another study showed that the 
pre-transplant TnT concentration was predictive of survival 
in the post-transplant period. Higher concentrations were 
associated with increased risk of fatal cardiovascular events 
[79]. A large study with over 2000 participants by Abedini 
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and colleagues found that CRP is similarly associated with 
major cardiovascular events in stable RTR [80]. Despite the 
confounding influence of renal function on the concentra-
tions of TnT and NT-proBNP, these and other circulating 
biomarkers may be suitable adjuncts to existing risk predic-
tion models for RTR.
Several recent reviews have also highlighted the poten-
tial use of physical biomarkers of cardiovascular disease 
for improving the accuracy of risk prediction [81, 82]. For 
example, pulse wave velocity (PWV) is a non-invasive meas-
ure of arterial stiffness and has been repeatedly shown to 
independently predict cardiovascular events and mortality 
in RTR [81]. Similarly, coronary artery calcification (CAC) 
scores obtained from cardiac computed tomography (CT) 
have been demonstrated to act as strong predictors of mortal-
ity in this population [82]. Further work is therefore required 
to clarify which biomarkers are most useful and how they 
should be incorporated into clinical practice.
Conclusion
Despite improvements in cardiovascular risk management 
and outcomes, cardiovascular disease remains a leading 
threat to graft and patient survival following renal trans-
plantation. In RTR there exists a unique combination of tra-
ditional and non-traditional cardiovascular risk factors. The 
accelerated risk of cardiovascular disease is often amplified 
by the effects of immunosuppression. As a result, risk pre-
diction models developed in the general population often 
under-estimate risk in RTR. The use of transplant-specific 
risk calculators may go some way towards overcoming this 
problem. Addition of cardiovascular biomarkers to these 
scores may improve accuracy but further work in this area 
is required. At present, aggressive management of traditional 
risk factors remains the cornerstone of effective cardiovascu-
lar disease prevention. However, other strategies to prolong 
optimal graft function and overcome the negative aspects 
of current immunosuppression regimens should also be 
considered.
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